SYH2043 / CSPC Pharma - LARVOL DELTA

Wantai Bio: The results of the phase III study of the nine-valent HPV vaccine are in line with expectations; the first-in-class triple antibody product has obtained FDA fast track qualifications [Google translation] (163.com) - "On April 10, according to the CDE official website, CSPC Pharmaceutical Group’s SYH2043 tablets were approved for clinical use and are planned to be combined with fulvestrant for the treatment of advanced breast cancer."

New trial • Breast Cancer • Oncology • Solid Tumor

Dose Escalation and Expansion Study of SYH2043 in Patients With Advanced Malignant Tumors (clinicaltrials.gov) - P1 | N=367 | Not yet recruiting | Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd.

Metastases • New P1 trial • Breast Cancer • Gastrointestinal Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Ovarian Cancer • Solid Tumor • ER • HER-2

CSPC (01093): Oral small molecule CDK inhibitor SYH2043 has been approved for clinical trials [Google translation] (Zhitong Finance) - "Zhitong Finance APP News, CSPC (01093) announced that SYH2043 developed by the Group has been approved by the State Drug Administration of the People's Republic of China, and can carry out clinical research in China....According to the announcement, SYH2043 is an innovative anti-tumor drug of oral small molecule CDK2/4/6 inhibitors with independent intellectual property rights....The Group will go all out to promote the clinical research of this product and strive to launch the product as soon as possible."

New trial • Oncology